Flinton Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Flinton Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-131	Closed	-$66K	–	892
2019 Q2	$66K	Sell	131 -41	-24%	-$28.9K	﹤0.01%	818
2019 Q1	$170K	Sell	172 -172	-50%	-$160K	0.01%	700
2018 Q4	$299K	Sell	344 -164	-32%	-$152K	0.01%	560
2018 Q3	$525K	Buy	508 +35	+7%	+$34.2K	0.02%	485
2018 Q2	$435K	Buy	473 +12	+3%	+$12.9K	0.01%	457
2018 Q1	$449K	Buy	461 +389	+540%	+$354K	0.02%	441
2017 Q4	$32K	Sell	72 -48	-40%	-$17.7K	﹤0.01%	830
2017 Q3	$50K	Sell	120 -15	-11%	-$5.65K	﹤0.01%	801
2017 Q2	$47K	Sell	135 -44	-25%	-$17K	﹤0.01%	799
2017 Q1	$92K	Hold	179	–	–	﹤0.01%	651
2016 Q4	$64K	Buy	+179	New	+$75.8K	﹤0.01%	679

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Flinton Capital Management's ATRA Position: Q3 2019 in Review

Flinton Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 131 shares — an estimated $66K sold.

Flinton Capital Management first reported a position in ATRA in Q4 2016 and held it in 11 quarters. The position peaked at $525K in Q3 2018. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

Flinton Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
Flinton Capital Management sold 131 Atara Biotherapeutics shares in Q3 2019, an estimated $66K.
Flinton Capital Management first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 11 quarters.
Flinton Capital Management's Atara Biotherapeutics position peaked at $525K in Q3 2018.
112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.